TD Cowen analyst Tyler Van Buren maintained a Buy rating on EyePoint Pharmaceuticals today and set a price target of $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight EyePoint Pharmaceuticals’ promising future prospects. The company has successfully completed enrollment for its Phase III trials, LUGANO and LUCIA, in a remarkably short period of seven months, demonstrating strong demand and efficient execution. These trials, aimed at treating wet age-related macular degeneration (wAMD), have enrolled over 400 patients each, showcasing the potential for a safe and durable treatment option.
Furthermore, EyePoint is on track to potentially become the first to market with a long-acting tyrosine kinase inhibitor (TKI) with a Q6M label, which could significantly differentiate it from competitors. The anticipated release of LUGANO data in mid-2026, followed by LUCIA data, is expected to be a major value-creating event. If successful, EyePoint plans to file a New Drug Application (NDA) shortly after, with the possibility of launching by the end of 2027, further supporting the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYPT in relation to earlier this year.